380 related articles for article (PubMed ID: 8330650)
1. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts.
Klingemann HG; Deal H; Reid D; Eaves CJ
Exp Hematol; 1993 Aug; 21(9):1263-70. PubMed ID: 8330650
[TBL] [Abstract][Full Text] [Related]
2. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
3. Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12.
Wong EK; Eaves C; Klingemann HG
Bone Marrow Transplant; 1996 Jul; 18(1):63-71. PubMed ID: 8831997
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 activation of human bone marrow in long-term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors.
Verma UN; Bagg A; Brown E; Mazumder A
Bone Marrow Transplant; 1994 Feb; 13(2):115-23. PubMed ID: 8205079
[TBL] [Abstract][Full Text] [Related]
5. Culture of normal and leukemic bone marrow in interleukin-2: analysis of cell activation, cell proliferation, and cytokine production.
Klingemann HG; Neerunjun J; Schwulera U; Ziltener HJ
Leukemia; 1993 Sep; 7(9):1389-93. PubMed ID: 8371589
[TBL] [Abstract][Full Text] [Related]
6. Differential kinetics of primitive hematopoietic cells assayed in vitro and in vivo during serum-free suspension culture of CD34+ blood progenitor cells.
Möbest D; Goan SR; Junghahn I; Winkler J; Fichtner I; Hermann M; Becker M; de Lima-Hahn E; Henschler R
Stem Cells; 1999; 17(3):152-61. PubMed ID: 10342558
[TBL] [Abstract][Full Text] [Related]
7. A clinically suitable ex vivo expansion culture system for LTC-IC and CFC using stroma-conditioned medium.
Bhatia R; McGlave PB; Miller JS; Wissink S; Lin WN; Verfaillie CM
Exp Hematol; 1997 Aug; 25(9):980-91. PubMed ID: 9257812
[TBL] [Abstract][Full Text] [Related]
8. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.
Klingemann HG; Wong E; Maki G
Biol Blood Marrow Transplant; 1996 May; 2(2):68-75. PubMed ID: 9118301
[TBL] [Abstract][Full Text] [Related]
9. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
10. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
11. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-12 (IL-12) alone or in synergistic combination with IL-2 for in vitro activation of human bone marrow: differential effects at different time points.
Verma UN; Mazumder A
Bone Marrow Transplant; 1995 Sep; 16(3):365-72. PubMed ID: 8535308
[TBL] [Abstract][Full Text] [Related]
13. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
14. Biological characterization of CD34+ cells mobilized into peripheral blood.
Lemoli RM; Tafuri A; Fortuna A; Catani L; Rondelli D; Ratta M; Tura S
Bone Marrow Transplant; 1998 Dec; 22 Suppl 5():S47-50. PubMed ID: 9989890
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity, growth, and phenotype of long-term IL-2 cultures of human NK and T lymphocytes.
Fuchshuber PR; Lotzová E; Pollock RE
Lymphokine Cytokine Res; 1991 Apr; 10(1-2):51-9. PubMed ID: 1651770
[TBL] [Abstract][Full Text] [Related]
16. [Effects of FPIL6/IL2 on the differentiation and proliferation of lymphoid in the ML-IC assay].
Fan EJ; Song JM; Xu SR; Zhao CH
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Feb; 24(1):30-5. PubMed ID: 12905836
[TBL] [Abstract][Full Text] [Related]
17. Effect of flt3 ligand on in vitro growth and expansion of colony-forming bone marrow cells from patients with aplastic anemia.
Wodnar-Filipowicz A; Chklovskaia E; Manz CY; Lyman SD; Nissen C
Exp Hematol; 1997 Jul; 25(7):573-81. PubMed ID: 9216732
[TBL] [Abstract][Full Text] [Related]
18. Generation of natural killer cells from long-term cultures of mouse bone marrow.
Vecchini F; Delfino D; Patrene KD; DeLeo A; Lu L; Herberman RB; Boggs SS
Nat Immun; 1993; 12(1):1-16. PubMed ID: 8431659
[TBL] [Abstract][Full Text] [Related]
19. IL-2-activated cord blood mononuclear cells.
Derzic S; Slone V; Sender L
Cytotherapy; 2005; 7(5):408-16. PubMed ID: 16236630
[TBL] [Abstract][Full Text] [Related]
20. Studies of W mutant mice provide evidence for alternate mechanisms capable of activating hematopoietic stem cells.
Miller CL; Rebel VI; Lemieux ME; Helgason CD; Lansdorp PM; Eaves CJ
Exp Hematol; 1996 Feb; 24(2):185-94. PubMed ID: 8641340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
